Propellants in asthma inhalers produce greenhouse gas emissions equivalent to driving 200 miles, yet most healthcare systems ...

Revenue for Q3 2025 was $17.11 million, an increase of 38% from $12.41 million in Q3 2024, marking a new all-time high and reflecting significant growth across all core divisions. For the nine months ...

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going ...

The stunning simulation created with Japan's ultra-fast supercomputer, represents almost 10 million neurons, 26 billion ...

So notwithstanding the buoyant share price, we think it's well worth asking whether DISA's cash burn is too risky. For the purposes of this article, cash burn is the annual rate a ...

FinQuery, a global provider of AI-enabled accounting automation software, today announced expanded support for FRS 102 lease accounting, enabling organisations across the UK, Ireland, and EMEA to ...

US scientists have designed a a free tool for adults aged between 30 and 59 to calculate their 30 year risk of developing the ...

Hill & Smith's (LON:HILS) stock is up by 3.4% over the past month. Given its impressive performance, we decided ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

TONMYA (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic taken once daily at bedtime for adults with fibromyalgia. The treatment was approved by the FDA on August 15, 2025, marking ...